Parameter
| Biomarker | HOXA9, PCDH17, POU4F2, ONECUT2 (urine panel) | Full name | Homeobox A9, Protocadherin 17, POU Class 4 Homeobox 2 , One Cut Homeobox 2 | Molecular Type | Nucleic acid (predicted mRNA or DNA) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis (hematuria patient triage) |
| Disease | Bladder Cancer (BC) | Disease Subtypes | / | ||
| Organ | Bladder | Test Sample / Technology Platform | Urine (platform not specified) | ||
| Pathobiological Mechanisms | Combines urinary markers to distinguish bladder cancer from benign hematuria; reduces unnecessary invasive procedures | ||||
| Clinical Availability Status | Research verification stage | ||||
| Notes and Dynamics | Targeted panel for high-risk hematuria populations; clinical trials needed | ||||